Researchers from the IBEC and the University of Barcelona (UB) have identified new biomarkers for non-small cell lung cancer, the most common lung cancer. The results, published in the journal Modern … Read more
IBEC researchers have identified new biomarkers of non-small cell lung cancer, the most common lung cancer. In the study they have discovered that certain characteristics of collagen fibers, which are … Read more
One of the great challenges in the fight against cancer is to design new technologies for a personalized treatment for each patient. Depending on the molecular characteristics —DNA mutations for … Read more
A team of researchers from IBEC and the Faculty of Medicine and Health Sciences at the University of Barcelona have designed a device based on microfluidic physics to predict the … Read more
IBEC researchers appear in different media for the recent study senior-authored by Joan Montero and first-authored by Albert Manzano, Senior Researcher and PhD student in IBEC’s Nanobioengineering group in which they have used a state-of-the-art analysis technique to evaluate new drug combinations to successfully treat acute lymphoblastic leukemia.
A study led by researchers from the Nanobioengineering Group at IBEC, in collaboration with other research centers and hospitals in Barcelona, uses a predictive biomarker to anticipate the success of drugs against rhabdomyosarcoma, which represents around 5 percent of childhood tumors . This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.
A study led by IBEC researchers from the Nanobioengineering group, uses a functional predictive biomarker to anticipate the effect of treatments against rhabdomyosarcoma, the most common soft-tissue cancer affecting childhood and adolescence.
This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.
IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.
Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.